Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that its PGDx Elio Plasma Resolve liquid biopsy assay has received CE marking.

The in vitro diagnostic uses next-generation sequencing to detect single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, and microsatellite instability in circulating cell-free DNA isolated from plasma samples to guide therapy selection for cancer patients. PGDx also markets a tissue-based version of the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.